The Application of Evidence-Based Principles of Care in Older Persons (Issue 1): Management of Osteoporosis

Journal of the American Medical Directors Association

Volumn 8, Issue 3 SUPPL. 2, 2007, Pages

  Zarowitz, Barbara J ^a,c   Stefanacci, Richard ^b   Hollenack, Kelly ^c   O'Shea, Terry ^c  

^a WAYNE STATE UNIVERSITY   (United States)

^b UNIVERSITY OF THE SCIENCES   (United States)

^c Omnicare Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ANTICONVULSIVE AGENT; BENZODIAZEPINE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DOXERCALCIFEROL; ESTROGEN; ETIDRONIC ACID; GLUCOCORTICOID; GONADORELIN ANTAGONIST; HEPARIN; IBANDRONIC ACID; NEUROLEPTIC AGENT; PAMIDRONIC ACID; PARATHYROID HORMONE[1-34]; PARICALCITOL; PHENOBARBITAL; PHENYTOIN; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; THYROID HORMONE; TILUDRONIC ACID; TRICYCLIC ANTIDEPRESSANT AGENT; VITAMIN D; ZOLEDRONIC ACID;

ALGORITHM; ARTICLE; BONE DENSITY; CASE MANAGEMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIAGNOSTIC ACCURACY; DIET SUPPLEMENTATION; DRUG CHOICE; DRUG COST; DUAL ENERGY X RAY ABSORPTIOMETRY; ELDERLY CARE; EVIDENCE BASED MEDICINE; FALLING; FRAGILITY FRACTURE; FRAIL ELDERLY; GERIATRIC CARE; HIGH RISK PATIENT; HUMAN; NONHUMAN; NURSING CARE; NURSING HOME PATIENT; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; RISK FACTOR; VEIN THROMBOSIS;

EID: 33847631712     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2006.12.008     Document Type: Article

References (30)

1. Guyatt G., and Rennie D. Users' Guides to the Medical Literature: A Manual for Evidence-based Clinical Practice (2002), AMA Press, Chicago, IL
2. Messinger-Rapport B.J. Evidenced-based medicine: Is it relevant to long-term care?. J Am Med Dir Assoc 5 (2004) 328-332
3. Sackett D.L., Straus S.E., Richardson W.E., Rosenberg W., and Haynes R.B. Evidence-Based Medicine. How to Practice and Teach Evidence-Based Medicine (2000), Churchill Livingstone, New York, NY
4. University of the Sciences in Philadelphia. Geriatric Pharmaceutical Care Guidelines (2005), Omnicare, Inc, Covington, KY
5. American Society of Consultant Pharmacists Research and Education Foundation. MDS-Med Guide (1999), American Society of Consultant Pharmacists Research and Education Foundation, Alexandria, VA
6. University of the Sciences in Philadelphia. Geriatric Pharmaceutical Care Guidelines (2006), Omnicare, Inc, Covington, KY
7. US Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General (2004), U.S. Department of Health and Human Services, Office of the Surgeon General, Rockville, MD. http://www.surgeongeneral.gov/library/bonehealth/content.html Available at: http://www.surgeongeneral.gov/library/bonehealth/content.html. Accessed July 8, 2005
8. Office of Technology Assessment, US Congress. Hip Fracture Outcomes in People Age 50 and Over-Background Paper. OTA-BP-H-120 (1994), US Government Printing Office, Washington, DC July
9. Zimmerman S.I., Girman C.K., Buie V.C., et al. The prevalence of osteoporosis in nursing home residents. Osteoporos Int 9 (1999) 151-157
10. Office of Technology Assessment, US Congress. Effectiveness and Costs of Osteoporosis Screening ad Hormone Replacement Therapy. Volume II: Evidence on Benefits, Risk and Costs. OTA0BP-H-144 (1995), US Government Printing Office, Washington, DC August
11. Majumdar S.R., Kim N., Colman I., et al. Incidental vertebral fractures discovered with chest radiography in the emergency department. Arch Intern Med 165 (2005) 905-909
12. Solomon D.H., Morris C., Cheng H., et al. Medication use patterns for osteoporosis: An assessment of guidelines, treatment rates, and quality improvement interventions. Mayo Clin Proc 80 (2005) 194-202
13. Kanis J.A., Milton III L.J., Christiansen C., Johnston C.C., and Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res 9 (1994) 1137-1141
14. American Geriatrics Society, and British Geriatrics Society and the American Academy of Orthopaedic Surgeons Panel on Falls Prevention. Guideline for the prevention of falls in older persons. J Am Geriatr Soc 49 (2001) 664-672
15. American Association of Clinical Endocrinologists Osteoporosis Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocrine Prac 9 (2003) 544-564
16. Medicare Part D Drug Benefit. Access to Covered Part D Drugs (423.120). Federal Register 70 (2005) 4537-4538
17. Watts N.B., Worley K., Solis A., Doyle J., and Sheer R. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: Results from a managed care administrative claims database. J Manage Care Pharm 10 (2004) 142-151
18. Fitzpatrick L.A. Secondary causes of osteoporosis. Mayo Clinic Proc 77 (2002) 453-468
19. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
20. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
21. Harris S.T., Watts N.B., Genant H.K., et al., Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. JAMA 282 (1999) 1344-1352
22. McClung M.R., Geusens P., Miller P.D., et al., Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344 (2001) 333-340
23. Chesnut III C.H., Silverman S., Andriano K., et al., PROOF Study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures study. Am J Med 109 (2000) 267-276
24. Rossouw M.E., Anderson G.L., Prentice R.L., et al., The Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
25. Cauley J.A., Robbins J., Chen Z., et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: The Women's Health Initiative randomized trial. JAMA 290 (2003) 1729-3528
26. Ettinger B., Black D.M., Mitlak B.H., et al., Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year, randomized, clinical trial. JAMA 282 (1999) 637-645
27. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344 (2001) 1434-1441
28. Karpf D.B., Shapiro D.R., Seeman E., et al., Alendronate Osteoporosis Treatment Study Groups. Prevention of nonvertebral fractures by alendronate. A meta-analysis. JAMA 277 (1997) 1159-1164
29. Boonen S., McClung M.R., Eastell R., et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: Implications for use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc 52 (2004) 1832-1839
30. Teriparatide (Forteo) [package insert]. Indianopolis, IN: Eli Lilly & Co; 2002.